Differential activation of STATs 3 and 5 during mammary gland development  by Philp, Janet A.C. et al.
l-EBS 17675 FEBS Letters 396 (1996) 77-80 
Differential activation of STATs 3 and 5 during mammary gland 
development 
Janet A.C. Philp, Thomas G. Burdon 1, Christine J. Watson* 
Division o.1' Molecular Biology, Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS. UK 
Received 17 September 1996 
Abstract We have investigated the activity of STAT family 
members throughout a mammary developmental cycle. Tran- 
scripts for Stat 5 were upregulated during pregnancy whilst 
STAT1 and STAT3 mRNAs were expressed at constant levels. 
DNA binding complexes containing both STAT5a and 5b showed 
differing affinities for two naturally occurring STAT5 binding 
~ites. In the involuting mammary gland STAT5 activity 
decreased whereas STAT3 was specifically activated. These 
observations reveal a complex pattern of activation of STAT 
tactors during mammary growth, differentiation and remodelling 
and provide the first evidence for the involvement of STAT3 in 
development of the mammary gland. 
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~. Introduction 
Signal transducer and activator of transcription (STAT) 
!actors are latent cytoplasmic transcriptional regulators acti- 
'ated by cytokines and growth factors. Janus kinases (JAKs) 
tssociate with cytokine receptors and phosphorylate STAT 
actors on a particular tyrosine residue. Activated STATs 
hen form either homo of heterodimers and translocate to 
he nucleus where they bind to variations of a consensus pa- 
indrornic 9 bp recognition sequence [1]. To date six STAT 
amily members have been identified. 
The cytokine prolactin (PRL) promotes the growth and 
,tifferentiation of the mammary gland. During lactation, 
i 'RL stimulates the sustained activation of STAT5, a factor 
hat  is essential for high level transcription of milk protein 
:genes [2,3]. STAT5 is encoded by two closely related genes, 
gTAT5a and 5b [4,5]. We have shown previously that the 
~roximal 400 bp promoter of the milk protein gene ~-lacto- 
globulin (BLG) has three STAT factor binding sites and that 
hese sites have different affinities for STAT5 [6]. Additional 
"actors that modulate growth of the mammary gland such as 
growth hormone, epidermal growth factor (EGF) and fibro- 
~last growth factor (FGF) have been shown to activate 
-;TATs 1, 3 and 5 in tissue culture cells. Therefore, the 
";TAT factor binding sites in the promoters of milk protein 
genes, such as BLG, may not only act as PRL response le- 
nents but also serve to integrate the array of signals that 
~'ontrol differentiation of the mammary gland. 
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We investigated the expression and binding activity of 
STATs 1, 3, 5a and 5b throughout the mammary gland devel- 
opmental cycle. STAT3 and STAT5 are activated in a reci- 
procal fashion, suggesting different roles for these factors dur- 
ing mammary development. Complexes containing STATs 5a 
and 5b are found from early pregnancy through lactation and 
have different relative affinities for the two highest affinity 
sites in the BLG promoter. Interestingly, STAT3 is most 
strongly activated uring early involution when apoptosis is 
initiated. 
2. Materials and methods 
2.1. RNA extraction and Northern analysis 
RNA was isolated from HCll cells and mouse mammary gland 
tissue at various tages of development by the acid-phenol-guanidine 
thiocyanate single-step method [7]. Following electrophoresis on a 
1.5% agarose gel containing 3.8% formaldehyde, RNA was trans- 
ferred to the Zetaprobe nylon membrane (Bio-Rad, Richmond, CA) 
and fixed by baking for 1 h at 65°C. Hybridisations were performed 
overnight at 65°C in buffer containing 0.25 M Na2HPO4 and 7% 
sodium dodecyl sulfate. Filters were washed extensively in 20 mM 
Na2HPOa, 5% sodium dodecyl sulfate at 65°C before autoradiogra- 
phy or quantitation. Equal loading of RNA on gels was confirmed by 
hybridisation with an oligonucleotide specific for the mouse 28S ribo- 
somal RNA. 
2.2. Western blot analysis 
Cell lysates were prepared from mouse mammary tissues by grind- 
ing in liquid nitrogen and then resuspending in lysis buffer (50 mM 
HEPES, pH 7.5, 5 mM EDTA, 150 mM NaC1, 30 mM sodium pyro- 
phosphate, 50 mM sodium fluoride, 100 ~tM sodium pervanadate, 
0.5% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 lag/ml 
aprotinin, 1 ~tg/ml pepstatin, 2 lag/ml eupeptin). The resulting solu- 
tion was passed through a 20 gauge needle and syringe and insoluble 
material removed by centrifugation at 15000×g at 4°C for 15 rain. 
Protein estimations were performed using the Pierce Kit. Mammary 
tissue samples (40 ~tg per lane) were heated to 95°C for 5 min with an 
equal volume of loading buffer and loaded onto polyacrylamide g ls, 
using the Biorad protean II system, with a 3% stacking el and a 10% 
resolving el. The gel was run overnight at 40 V. 
Protein was transferred to nitrocellulose using an LKB Multiphor 
system run at 4°C, 8 mA/cm 2for 1 h. Loading was checked by Coo- 
massie staining of the blotted gel. Blocking was achieved with 5% 
BSA in PBSFfween (0.1%) for 1 h at room temperature. Primary 
antibodies were added at a dilution of 1/1000 in 5% BSA in PBS/ 
Tween. Specifically bound antibody was detected using the ECL Sys- 
tem (Amersham) and recorded using X-ray film. 
2.3. Nuclear extracts and EMSA 
Nuclear extracts were prepared from mammary tissue using the 
method of Dignam with minor modifications [6]. Daudi cells were 
treated with 1000 units IFN-c~/ml for 20 min and YHHH cells (deri- 
vatives of MOLT4) with 1000 units IFN-a/ml for 20 rain before the 
preparation of nuclear extracts, which were kindly provided by Dr. 
John Girdlestone, (University of Birmingham, UK). EMSA were car- 
ried out as previously described [6]. Binding sites were created by 
annealing the following oligonucleotide pairs: STM 5' GATTCCGG- 
GAACCGCT 3' and 5' ACGCGGTTCCCGGAATC 3' and A3S 5' 
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GATCTCTACCAGGAACCGTCT 3' and 5' GATCAGACGGTTC- 
CTGGTAGA 3'. Antibody supershift analysis was carried out by the 
addition of antibody to the binding reaction for 2 h at 4°C before the 
addition of radiolabelled probe. The STAT1 antibody was purchased 
from Transduction Laboratories (G16930/L6) and STAT3 (sc-482), 
STATSa (so-1081) and STAT5b (sc-835) were purchased from Santa 
Cruz. The phospho-specific STAT3 (Tyr-705) antibody kit was from 
NEB. 
2.4. Quantitation 
Data were quantitated with a Molecular Dynamics Phosphorimager 
system (Sunnyvale, CA). 
3. Results 
3.1. Differential transcriptional regulation of STA T genes 
during mammary gland development 
To determine which STAT factors are expressed in the 
mammary gland, RNA from mouse mammary glands at var- 
ious stages of pregnancy and lactation was analysed on 
Northern blot hybridised with partial cDNA clones for 
STATs 1, 3, 4 and 5 (Fig. 1). The sizes of the STAT tran- 
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Fig. 1. Northern blot analysis of mRNA levels of 4 members of the 
STAT family of transcription factors during mammary gland devel- 
opment. Total RNA (10 Ixg) was fractionated, blotted and hybri- 
dised with a2P-labelled STAT-specific DNA probes spanning the 
SH2 domain and a cDNA for ~-casein. Autoradiography was for 
2-7 days following STAT hybridisation and approx. 2 h for the 
[3-casein hybridisation. 
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Fig. 2. Western blot analysis of STAT protein levels during mam- 
mary development. Whole cell protein extracts (40 ~tg) of mammary 
tissue were run on SDS-PAGE gels, blotted, probed with antibodies 
specific for STATs 1, 3, 5a and 5b (Santa Cruz and Transduction 
Labs) and detected with the ECL system (Amersham). p, preg- 
nancy; L, lactation; I, involution. 
scripts found in the mammary gland corresponded with those 
previously reported for other tissues [5,8,9]. Low steady-state 
levels of STAT4 RNA were detected uring early develop- 
ment (virgin and days 5 and 10). In contrast, STATs 1 and 
3 were expressed at fairly constant levels whilst STAT5 (a and 
b) was dramatically upregulated during late gestation to reach 
a peak just before birth. STAT5 was detected in virgin mam- 
mary tissue and was expressed at low levels until day 13 of 
gestation, when differentiation of the epithelial cells com- 
mences. Because of the heterogeneity of mammary tissue, 
RNA from HC 11 mammary epithelial cells, originally derived 
from a mid-pregnant mouse, was also included in this analy- 
sis. STATs 1, 3 and 5 were all expressed suggesting that these 
factors are expressed in the epithelial compartment. In con- 
trast, STAT4 was not detected suggesting that this STAT is 
expressed in the non-epithelial cells. The downregulation of
STAT5 steady-state RNA levels during lactation, when the 
milk protein [5-casein is maximally expressed (lane 6), was 
surprising. We therefore xamined the levels of these STAT 
proteins. 
3.2. STAT5a protein is strongly developmentally regulated 
compared to STA T5b, STA T1 and STA T3 
Total protein was analysed by Western blot analysis with 
antibodies pecific for STATs 1, 3, 5a and 5b. Two bands 
were observed for STATI which probably correspond to the 
p91 and p84 alternatively spliced isoforms. Both proteins were 
expressed at a fairly constant level from mid-gestation on- 
wards, with a small increase in abundance in involution. 
The pattern for STAT3 was similar, although in this case a 
single species was observed. The STAT5b-specific antibody 
reacted with two closely spaced bands. The upper band ap- 
pears to be developmentally regulated since it is present from 
day 15 onwards and throughout lactation, disappearing dur- 
ing involution. This band may be an additional isoform of 
STAT5b or a differently phosphorylated form. STAT5a shows 
a dramatic increase from days 15 to 17 of pregnancy whilst 
STAT5b does not. This does not correlate with the RNA 
expression profiles since STAT5a and STAT5b are expressed 
at similar levels [10] and the peak mRNA level occurs before 
lactation. 
3.3. STA Ts 5a and 5b form heterodimers throughout mammary 
gland development and have different affinities for the two 
sites A3S and STM 
STAT factors have been shown to form heterodimers. Stim- 
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I ig. 3. Analysis of STAT5 heterodimerisation. Antibody supershift 
~ mlysis was carried out with mammary nuclear extracts from days 
] 5 and 17 of pregnancy and days 2 and 10 of lactation using anti- 
b 9dies which specifically recognise ither STAT 5a or 5b or STAT1. 
I l (A), the STM site was used as probe whereas in (B), the A3S 
s te was the probe. 
l lation of cells with IL-6 induces the formation of both 
l omodimers of STAT1 and STAT3 and heterodimers of 
,~TATsl and 3 [1]. Given the high degree of similarity between 
1-oth STAT5 sequences, it seemed likely that STAT5a and 
~TAT5b could form heterodimers. To investigate this possi- 
1 ility and to determine whether the ratio of homo- to hetero- 
timers changes during mammary gland development, we car- 
~ed out antibody supershift EMSA. The results, shown in 
~'ig. 3 (upper panel), show that similar proportions of 
:TAT5a and 5b bind to the STM site (77% 5a compared to 
',-1% 5b). This indicates that at least 59% of the bound corn- 
• lexes are heterodimers of STATs 5a and 5b, since addition of 
:~ oth antibodies abolished binding (data not shown). Similar 
~sults were obtained for the other developmental time points 
, xamined (days 15 and 17 of pregnancy and day 2 lactation) 
nd virgin and days 5 and 10 of pregnancy (data not shown). 
We have previously shown that the three STAT sites in the 
BLG promoter have different affinities for STAT5 in the lac- 
tating mammary gland [6]. In Fig. 3 (lower panel), we show 
'~hat his different affinity is reflected in the different relative 
atios of STAT5a and 5b dimers which bind to the sites STM 
.nd A3S. Antibody supershift analysis with the A3S probe 
bows that most (89%) of the STAT binding activity in the 
0-day lactation sample contains STAT5a. However, a 
',TAT5b-specific antibody reduced binding by only 75%. 
"his result could suggest that heterodimers of 5a and 5b 
, ind preferentially to the STM site whilst homodimers of 5a 
rave a higher affinity for the A3S site. 
'.4. STATs  1 and 3 are activated uring earl), apoptosis 
The expression of milk protein genes is downregulated dur- 
ng the involution and remodelling of the mammary gland. 
'~Ve showed in Fig. 2 that the levels of STAT5a and 5b protein 
.re decreased uring early involution (day 3 following forced 
veaning at day 6 of lactation). This decrease was not observed 
:or STAT1 and STAT3. It was of interest herefore to deter- 
nine whether the relatively higher levels of these STATs in the 
nvoluting mammary gland has functional significance. Fig. 4 
hows an EMSA analysis of nuclear extracts from day 10 
actating and day 3 involuting mammary glands with the 
k3S STAT binding site. Two complexes were formed with 
he involuting sample (Fig. 4, lane 6) compared to a single 
~and for the day 10 lactation sample which appears to consist 
.dmost entirely of STAT5 (Fig. 4, lane 2). Addition of anti- 
~odies to STAT3 practically abolished both bands whilst anti- 
~odies to STAT1 abolished the upper band (Fig. 4, lanes 9,10, 
espectively). The remaining complex is likely to be STAT5. 
Similar results were obtained with the lowest affinity BLG site 
A1 (data not shown). 
The activation of STAT3 during involution was confirmed 
using an antibody which specifically recognises tyrosine phos- 
phorylated STAT3 (on residue Tyr 705). In Fig. 5A shows a 
Western blot analysis of mammary developmental time points 
with the STAT3 phospho-specific antibody. Highest levels are 
observed in the involution sample whilst phosphorylated 
STAT3 is also present from day 5 of pregnancy, a period of 
high epithelial cell proliferation, decreasing through to day 15 
of pregnancy. Fig. 5B is the same blot re-probed to show the 
total STAT3 protein. By day 3 of involution, apoptosis (pro- 
grammed cell death) has been initiated in the mammary 
epithelial cells. It is possible that this STAT activation is oc- 
curring in the fat cells or in invading macrophages although, 
at this early time in remodelling of the gland, the abundance 
of macrophages i just beginning to rise [11]. In order to 
investigate the time course of STAT3 activation, samples 
from days 1, 3, 4 and 6 of involution were examined for 
phosphorylated STAT3. The results, wlfich are shown in 
Fig. 5C, show that STAT3 is activated within a day following 
forced weaning and levels remain constant until day 6. 
These results demonstrate that activation of STAT3 is a 
feature of involution in the mammary gland and suggest 
that STAT3 activation in the secretory epithelial cells is an 
early event in the apoptotic pathway. 
4.  D iscuss ion  
The importance of STAT5 as a mediator of PRL induced 
transcription of milk protein genes is well established [12]. 
However the roles of the two STAT5 genes and other 
STAT family members in the development of the mammary 
gland has not been determined. 
Transcripts encoding STATs 1, 3, 4 and 5 were found in the 
mammary gland. STAT4 mRNA was detected only in undif- 
ferentiated mammary tissue but not in a mammary cell line, 
indicating that its expression is limited to non-epithelial cells 
or a subset of undifferentiated pithelial cells. STAT4 has a 
restricted pattern of expression in the mouse and is only de- 
tected at high levels in the testes, thymus, spleen and myeloid 
cells [9]. The mammary gland does contain lymphatic tissue 
and this may be the source of STAT4 expression. In contrast 
to STATs 1 and 3, STAT5 mRNA increased uring preg- 
nancy and paralleled the rise in casein mRNA, indicating 
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Fig. 4. Activation of STATI and STAT3 during mammary gland 
involution. Antibody interference analysis with extracts from day 10 
lactation (lanes 1 5) and day 3 involution (lanes 6-10) and A3S 
probe, Extracts were pre-incubated with the antibodies indicated 
above each lane. Control extracts are Daudi cells treated with 
IFN-ot for 20 min (lanes 11,12) which induces primarily STATI and 
YHHH cells (derivatives of MOLT4) also treated with IFN-c~ for 
20 min which induces predominantly STAT3 (lanes 13-15). These 
extracts were kindly provided by Dr. John Girdlestone (University 
of Birmingham). 
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Fig. 5. Detection of tyrosine phosphorylated STAT3 during mammary gland development using a phospho-specific antibody. Whole cell protein 
extracts (20 gg) of mammary tissue were run on SDS-PAGE gels, blotted, and probed with antibodies to detect either tyrosine phosphorylated 
STAT3 (A) or total STAT3 (B) using the NEB PhosphoPlus STAT3 (Tyr-705) antibody kit. In (C), involution mammary samples were Western 
blotted and probed with antibodies to detect either tyrosine phosphorylated STAT3 (left) or total STAT3 (right). 
that STAT5 might regulate its own transcription. Such an 
autoregulatory loop has been described in rat hepatoma cells 
where STAT3 is induced 3-5-fold by IL-6 [13], a cytokine that 
activates STAT3. 
The decrease in STAT mRNAs during lactation is a phe- 
nomenon that affects many genes including housekeeping 
genes [14] but did not suppress levels of STAT5a and 5b 
protein. Complexes containing STAT5 heterodimers and 
homodimers were detected throughout pregnancy and lacta- 
tion. However, the complexes exhibited preferential binding to 
different binding sites. How this selective binding affects milk 
protein gene expression is not known. Nevertheless, this ob- 
servation together with the marked increase in STAT5a rela- 
tive to 5b during late pregnancy, provides an additional mech- 
anism for explaining the unique temporal expression patterns 
of different milk protein genes during gestation. Since the 
STAT binding sites in the promoters of these genes have dif- 
ferent sequences, it is possible that a genes expression reflects 
both the sequence preferences of STAT5a and STAT5b homo 
and heterodimers and their relative abundance. 
We have detected phosphorylated STAT3 during early 
pregnancy and involution in the mammary gland suggesting 
that STAT3 may play a role in proliferation and apoptosis. 
This correlates with our earlier observations that STATs 1 
and 3 are highly activated in breast carcinomas [15]. In this 
context, it is interesting that overexpression f STAT3 results 
in apoptosis in M1 cells [16]. Recently, a dominant negative 
form of STAT5 was shown to inhibit partially the growth of 
Ba/F3 cells implicating STAT proteins in cell cycle regulation 
[17]. Furthermore, it has been demonstrated that STAT1 me- 
diates the suppression of cell growth in response to IFN- 7 by 
stimulating transcription of the cell cycle regulator 
p21 wAF1/cIP1 [18]. The reciprocal pattern of activation of 
STAT5 and STAT3 suggests that these STAT factors have 
distinct roles in the growth and remodelling of the mammary 
gland. Although it is known that PRL activates STAT5, it 
remains to be determined which factors activate STAT3 in 
the mammary gland and whether this is important for growth 
and apoptosis. 
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